Ionis Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 927
- Market Cap
- $7B
- Introduction
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
News
Arrowhead Pharmaceuticals Files Patent Lawsuit Against Ionis Over Plozasiran FCS Treatment
Arrowhead Pharmaceuticals filed a declaratory judgment complaint against Ionis Pharmaceuticals in Delaware federal court, challenging the validity of Ionis's U.S. Patent No. 9,593,333 and asserting non-infringement by plozasiran.
Olezarsen Achieves 60% Triglyceride Reduction in Phase 3 Trial for Cardiovascular Risk Patients
Monthly olezarsen injections reduced triglyceride levels by approximately 60% at 6 months compared to placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk.
Raina Biosciences Publishes Breakthrough AI Platform for mRNA Therapeutics in Science
Raina Biosciences announced publication of its GEMORNA platform data in Science, marking the world's first generative AI platform purpose-built for mRNA design and optimization.
Personalized ALS Drug Shows Breakthrough Results, Slowing Disease Progression by More Than Half
A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.
Ionis Pharmaceuticals Reports Strong Q2 2025 Results, Raises Guidance on TRYNGOLZA Success
Ionis Pharmaceuticals delivered $19 million in net product sales for TRYNGOLZA in Q2 2025, driving a doubling of total revenue to $452 million compared to the same period last year.
BioVie Strengthens Board with Neuroscience and Finance Veterans as Bezisterim Advances Through Phase 2 Trials
BioVie Inc. appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors to support the company's neurological and liver disease drug development programs.
Donidalorsen Shows 62% Reduction in HAE Attacks When Patients Switch from Other Prophylactics in Phase 3 Study
Patients with hereditary angioedema who switched to donidalorsen from other prophylactic treatments experienced a 62% further reduction in mean monthly attack rate compared to baseline.
Sarepta Therapeutics Implements $400 Million Cost-Cutting Plan Amid Regulatory Challenges for Gene Therapy
Sarepta Therapeutics announced a $400 million annual cost-savings initiative in July 2025, including a 36% workforce reduction of 500 employees to achieve financial sustainability through 2027.
Biogen and Acumen Advance Alzheimer's Research with Long-Term Data and Novel Targeting Approaches at AAIC 2025
Biogen presents 48-month data from LEQEMBI's Clarity AD open-label extension study and introduces subcutaneous formulation for maintenance dosing at AAIC 2025.
Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results
Biogen's salanersen (BIIB115/ION306) demonstrated substantial slowing of neurodegeneration and clinically meaningful motor function improvements in children with spinal muscular atrophy previously treated with gene therapy.